SHRED Shotz cannabis beverage launched by Organigram Global (OGI)

Rhea-AI Filing Summary

Organigram Global Inc. is introducing SHRED Shotz, a compact 65 mL cannabis beverage under its SHRED brand, powered by its FAST™ nanoemulsion technology designed for a roughly 15-minute onset. Each bottle contains 10 mg of THC and will launch in Blue Razzberry and OG Lemonade flavours.

SHRED Shotz is intended to extend the SHRED brand, which generated over $200 million in retail sales in 2025, into shot-sized beverages aimed at convenience and faster-onset effects. The product is expected to be available in March in Ontario and Atlantic Canada, with additional provinces to follow.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2026

Commission File Number: 001-38885

ORGANIGRAM GLOBAL INC.

(Translation of registrant’s name into English)

145 King Street West, Suite 1400

Toronto, Ontario ,Canada M5H 1J8

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [ ]           Form 40-F [ X ]

SUBMITTED HEREWITH

Exhibits

99.1 News Release dated March 5, 2026

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ORGANIGRAM GLOBAL INC.

/s/ Greg Guyatt

Greg Guyatt

Chief Financial Officer

Date: March 5, 2026

Organigram Global Expands FAST™ Innovation Platform with SHRED Shotz, Leveraging SHRED Brand Equity

FAST™-powered SHRED Shotz extends the SHRED brand into shot-sized beverages

Toronto, Ontario - March 5, 2026 - Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), Canada’s #1 cannabis company by market share1 is pleased to announce the launch of SHRED Shotz, a compact, single-serve 65ml cannabis beverage powered by FAST™, Organigram’s fast-acting nanoemulsion technology platform designed to deliver a 15-minute onset2.

This launch reflects Organigram’s focus on differentiated innovation while leveraging the scale of SHRED, one of the Company’s best-known brands. SHRED surpassed $200 million in retail sales in 20253, underscoring the brand’s momentum and track record of expansion into new formats. With SHRED Shotz, Organigram is introducing a compact format designed to help broaden the beverage category and bring new consumers into the segment.

“SHRED Shotz is another clear example of how we successfully translate consumer insights into meaningful product innovation” said Eric Williams, Organigram Global’s Vice President of Marketing. “With FAST™ powering the formulation, we are bringing that technology into a compact, single-serve beverage under the SHRED brand,

1 Based on multiple sources (Hifyre, Weedcrawler, provincial boards, internal modelling) as of December 30, 2025.

2 Onset is defined in terms of mean blood concentrations. Onset times may vary.

3 Based on multiple sources (Hifyre, Weedcrawler, provincial boards, internal modelling) as of September 30, 2025.

allowing us to expand into new occasions with a format built for taste, convenience and predictability.”

About FASTtm nanoemulsion technology

FASTtm is a patent-pending nanoemulsion technology platform designed to support a faster-onset ingestible experience and consistent performance across product formats. Organigram has previously reported clinical pharmacokinetic (PK) research completed through the Product Development Collaboration, a joint research and development initiative with BAT, showing that, depending on the ingestible format, FASTtm delivered up to approximately 50% faster onset, improved bioavailability (the amount absorbed into the bloodstream), and up to double cannabinoid delivery at peak compared with traditional ingestible products4.

SHRED Shotz are expected to be available for sale at Canadian cannabis retailers sometime in March in Ontario and Atlantic Canada, with availability in other provinces expected to follow soon after. Each compact 65 mL bottle contains 10 mg THC and will be available in Blue Razzberry and OG Lemonade flavours.

About Organigram Global Inc.

Organigram Global Inc. is a NASDAQ Global Select Market and TSX listed company whose wholly owned subsidiary, Organigram Inc., is a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada. Through its acquisition of Collective Project, Organigram Global participates in the U.S. and Canadian cannabinoid beverage markets. Organigram is focused on producing high-quality cannabis for adult consumers, as well as developing international business relationships to extend the Company's global footprint. Organigram has developed and acquired a portfolio of cannabis brands, including Edison, Big Bag O’ Buds, SHRED, SHRED’ems, Monjour, Tremblant Cannabis, Collective Project, Trailblazer, BOXHOT and DEBUNK. Organigram operates cultivation and processing facilities in Moncton, New Brunswick and Lac Supérieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba. The Company operates two additional cannabis processing facilities in Southwestern Ontario; one in Aylmer and the other in London. The facility in Aylmer houses best-in-class CO2 and Hydrocarbon extraction capabilities, and is optimized for formulation refinement, post-processing of minor cannabinoids, and pre-roll production. The facility in London is optimized for labelling, packaging, and national fulfillment. The Company is regulated by Health Canada under the Cannabis Act and the Cannabis Regulations (Canada).

4 Preliminary PK study results released August 07, 2024.

Forward-Looking Information

This news release contains forward-looking information. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “estimates”, “intends”, “anticipates”, “believes” or variations of such words and phrases or statements that certain actions, events, or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information including expectations regarding market performance involves known and unknown risks, uncertainties and other factors that may cause actual results, events, performance or achievements of Organigram Global to differ materially from current expectations or future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information include timing for launch of products, changes in the regulatory landscape, acceptance of products and different product forms in the local market and factors and risks disclosed in the Company’s most recent annual information form, management’s discussion and analysis, and other Company documents filed from time to time on SEDAR+ (see www.sedarplus.ca) and filed or furnished to the Securities and Exchange Commission on EDGAR (see www.sec.gov). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed timeframes or at all. The forward-looking information included in this news release is made as of the date of this news release and the Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

Media Contact

Max Schwartz, Director of Investor Relations investors@organigram.ca

Mark McKay, Director of Communications mark.mckay@organigram.ca

FAQ

What did Organigram Global Inc. (OGI) announce in this Form 6-K?

Organigram Global Inc. announced the launch of SHRED Shotz, a 65 mL, single-serve cannabis beverage powered by its FAST™ nanoemulsion technology, extending its SHRED brand into shot-sized drinks with a faster-onset ingestible experience and convenient format for adult consumers.

What is SHRED Shotz and how does it fit Organigram Global’s (OGI) SHRED brand?

SHRED Shotz is a compact 65 mL cannabis beverage containing 10 mg THC, offered under Organigram’s SHRED brand. It builds on SHRED’s momentum, which surpassed $200 million in retail sales in 2025, by expanding the brand into convenient, shot-sized beverage formats.

How does Organigram Global’s FAST™ technology work in SHRED Shotz?

FAST™ is a patent-pending nanoemulsion technology platform designed to support faster-onset ingestible cannabis products. Clinical pharmacokinetic research cited by Organigram indicates FAST™ can deliver up to approximately 50% faster onset, improved bioavailability, and up to double cannabinoid delivery at peak versus traditional ingestible products.

When and where will Organigram Global’s SHRED Shotz be available in Canada?

SHRED Shotz are expected to be available at Canadian cannabis retailers sometime in March in Ontario and Atlantic Canada. Organigram Global also expects availability in other Canadian provinces to follow, broadening access to this compact, single-serve cannabis beverage format across the country.

What THC content and flavours will Organigram Global’s SHRED Shotz offer?

Each SHRED Shotz bottle contains 10 mg of THC in a 65 mL serving. Organigram Global plans to launch the product in at least two flavours, Blue Razzberry and OG Lemonade, targeting consumers looking for taste, convenience, and a predictable ingestible cannabis experience.

How does Organigram Global’s FAST™ research support SHRED Shotz positioning?

Organigram cites preliminary pharmacokinetic study results indicating FAST™ can provide up to approximately 50% faster onset, better bioavailability, and up to double cannabinoid delivery at peak. This research supports positioning SHRED Shotz as a faster-onset, predictable cannabis beverage compared with traditional ingestible products.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EX-99.1 14.7 KB